Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C27H31N7O2 |
| Molecular Weight | 485.5807 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=C(NC2=NC=CC(=N2)C3=CNC4=CC=CC=C34)C=C(NC(=O)C=C)C(=C1)N(C)CCN(C)C
InChI
InChIKey=IQNVEOMHJHBNHC-UHFFFAOYSA-N
InChI=1S/C27H31N7O2/c1-6-26(35)30-22-15-23(25(36-5)16-24(22)34(4)14-13-33(2)3)32-27-28-12-11-21(31-27)19-17-29-20-10-8-7-9-18(19)20/h6-12,15-17,29H,1,13-14H2,2-5H3,(H,30,35)(H,28,31,32)
AZ5104 is a demethylated metabolite of Osimertinib. AZ5104 potently and irreversibly inhibits both wild-type and mutant (exon 19 and L858R) EGFR and demonstrates good anti-cancer effect in both cell-based and in vivo experiments. Although AZ5104 was tested on preclinical models of lung cancer, it is used only in the prodrug form.
Originator
Approval Year
Sample Use Guides
| Name | Type | Language | ||
|---|---|---|---|---|
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
1421373-98-9
Created by
admin on Sat Dec 16 14:37:13 GMT 2023 , Edited by admin on Sat Dec 16 14:37:13 GMT 2023
|
PRIMARY | |||
|
71496460
Created by
admin on Sat Dec 16 14:37:13 GMT 2023 , Edited by admin on Sat Dec 16 14:37:13 GMT 2023
|
PRIMARY | |||
|
2DWZ6SE1E1
Created by
admin on Sat Dec 16 14:37:13 GMT 2023 , Edited by admin on Sat Dec 16 14:37:13 GMT 2023
|
PRIMARY |
PARENT (METABOLITE ACTIVE)
SUBSTANCE RECORD
